CytoDyn announces benefactor committed funding to support EAP

CytoDyn (CYDY) announced that a benefactor has formally committed funding to support the Company’s Expanded Access Program, EAP, for patients with triple-negative breast cancer. “We are honored by this benefactor’s commitment to accelerating patient access to promising cancer therapies such as leronlimab,” said Jacob Lalezari, M.D., CEO of CytoDyn. “This support allows us to responsibly broaden the availability of leronlimab while continuing to advance our promising clinical programs as we generate data to inform future regulatory pathways.”